The cell dissociation market is projected to achieve a valuation of USD 352.91 million by 2023, with a CAGR of 13.55% from 2023 to 2033. The cell dissociation business is projected to have a turnover of USD 1,257.59 million by 2033.
Cell dissociation is an essential activity in biopharmaceutical research since it’s involved in medication development and disease explanation. As a result, higher research and development spending by biopharmaceutical companies is spearheading cell dissociation market expansion.
The sector is expanding to assist researchers and pharmaceutical companies in their efforts to study, and use cells. Since cell culture technology played a significant role in identifying therapeutic and innovative diagnostic alternatives, the pandemic increased demand.
The cell dissociation market is expanding due to the crucial tools that culturing techniques for vaccine development. The primary factor fueling the cell dissociation industry expansion is the increased emphasis on creating cell-based therapies. Market expansion is being fueled by an increase in clinical trials, FDA approvals, and strategic moves by leading companies.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Although, in several areas, ethical constraints and concerns about the use of cell-based research limit the progress of cell biology.
The cell dissociation market was worth USD 200.25 million in 2018, with a CAGR of 12% from 2018 to 2022. By 2022, the cell dissociation business reached a revenue of USD 315.10 million.
The market, on the other hand, is estimated to be worth USD 352.91 million by 2023, with a CAGR of 13.55% through 2033. By 2033, the cell dissociation business is expected to have a revenue of USD 1,257.59 million.
Shift Toward Enzymatic Dissociation: Conventionally, mechanical methods were commonly used to break down tissue and cells. In recent years, there has been a significant shift toward enzymatic methods, which are efficient and gentler on cells.
Development of New Dissociation Reagents: Over the years, researchers have developed new and improved dissociation reagents, including proteolytic enzymes and chelating agents. This has enabled the dissociation of a wider range of cell types and tissues with greater accuracy and efficiency.
Increased Demand for Animal-free and Xeno-free Dissociation Reagents: With the rise of regenerative medicine and cell-based therapies, there has been a growing demand for animal-free and xeno-free dissociation reagents. It helps to reduce the risk of contamination and improves cell viability.
Growth in Stem Cell Research: The use of cell dissociation methods has become increasingly important in the field of stem cell research. As dissociated cells are often used to generate induced pluripotent stem cells (iPSCs) and other cell types for research and therapeutic applications.
Advancements in Cell-based Therapies: The development of cell-based therapies, such as CAR-T cell therapy and stem cell transplantation, has driven dissociation reagents demand and enzymes for the isolation and therapeutic cell expansion.
Growing Research in Drug Discovery: The use of cell-based assays in drug discovery has led to increased demand for dissociation reagents and enzymes to isolate and culture cells for high-throughput screening.
| Attributes | Details |
|---|---|
| Cell Dissociation Market HCAGR (2018 to 2022) | 12% |
| Cell Dissociation Market CAGR (2023 to 2033) | 13.55% |
| Cell Dissociation Market Size (2022) | USD 315.10 million |
| Cell Dissociation Market Size (2023) | USD 352.91 million |
| Cell Dissociation Market Size (2033) | USD 1,257.59 million |
Principal Consultant
The rising interest in personalized medicine and regenerative medicine is set to propel the demand for cell dissociation solutions. Cell dissociation is a critical stage that involves evaluating a patient's genetic profile to determine specific treatment options.
Cell dissociation materials are used to develop cell-based therapies and regenerative medicine solutions. As chronic and infectious diseases grow increasingly widespread, demand for cell dissociation products is likely to rise. Cell-based assays are used to diagnose and treat diseases such as cancer, Alzheimer's disease, and diabetes.
The technological advancements in cell dissociation products are propelling the market's revenue. With the development of reagents and kits that provide efficient cell dissociation, the usage in research and development applications may increase.
The increased application of automation in cell dissociation is positively influencing market revenue growth. By reducing human error, automating the cell dissociation processes boosts productivity.
Another element promoting the uptake of automated cell dissociation systems is the growing need for high-throughput screening in drug discovery and development. The utilization of products to rise as integrated systems that combine cell dissociation with subsequent processing procedures is evolved.
The increased requirement for research and development in biopharmaceutical firms is a key reason driving cell dissociation market expansion. The favorable financing landscape for cancer research and the rising incidence and prevalence of diseases stimulate market growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The rising expense of cell-based research and the lack of infrastructure for cell-based research in developing nations may stymie market expansion. The intricacies of cell dissociation operations, as well as a scarcity of qualified personnel limit cell dissociation market revenue growth.
The growing emphasis on customized medicine and increased government support for cell-based research is expected to deflate market growth. Alternative cell dissociation procedures, such as sonication and freeze-thaw cycles, are expected to limit market revenue growth. Although, Small firms and new entrants may pose a threat to the growth of the cell dissociation industry.
| Attribute | Details |
|---|---|
| Enzymatic dissociation Segment Share | 47.9% |
| Leading CAGR Segment | Non-enzymatic Segment |
In 2023, the enzymatic dissociation segment dominated the global industry and held a significant share. Enzymatic dissociation is a technique that uses enzymes to break down the cut-up tissue fragments, freeing the cells from the tissue. Many types of enzymes are utilized in the dissociation process, and they can also be used in tandem.
All enzymatic dissociations are more successful and efficient in separating mononuclear cells from the spinal cord and brain. From 2023 to 2033, the non-enzymatic segment is expected to rise at a significant CAGR.
The enzyme-free formulation aids in the preservation of the functional and structural integrity of cell surface proteins. It also has the advantage of avoiding the cytotoxic effects of chelating drugs. The usage of animal-derived components is subjecting biopharmaceutical manufacturers to increased regulatory scrutiny.
Non-enzymatic products for cell culture are needed, which might accelerate category expansion. The solution is not recommended for cells with unique sticky qualities. The biopharmaceutical sector has created a Papain Dissociation Solution for difficult-to-remove cell lines.
| Attribute | Details |
|---|---|
| Tissue Dissociation Type Segment Share | 56.55% |
| Leading CAGR Segment | Cell Detachment Type Segment |
The industry has been divided into two types: tissue dissociation and cell detachment. The tissue dissociation type segment led the global industry in 2022, accounting for a huge proportion.
The segment may continue to increase at a steady rate, retaining its dominant position in the global market. Factors such as the increased focus of biopharmaceutical and pharmaceutical firms on the development of monoclonal antibodies and therapy customization may drive the expansion of this segment.
Cell detachment type segment, on the other hand, is expected to develop at a significant rate during the projection period. Cell detachment is essential in the culture of adherent cells. The most prevalent method of separation is trypsinization.
Increasing investment in cell culture product launches and strategic initiatives by leading industry players are among the fundamental factors driving this segment's growth.
| Attribute | Details |
|---|---|
| Pharmaceutical and Biotechnology Companies Segment Share | 71.60% |
| Leading CAGR Segment | Pharmaceutical and Biotechnology Companies Segment |
The industry has been subdivided into pharmaceutical and biotechnology enterprises, as well as research and academic institutes, based on end-users. During the projection period, the category is projected to develop at a considerable CAGR while maintaining its prominent position in the global market.
This segment's significant portion and rapid growth can be due to the extensive usage of cell dissociation enzymes in pharmaceuticals. Collagenase and trypsin are key enzymes for preserving solid tissues and adherent cells for culturing and research.
Cell tissue disaggregation and dissociation represent the beginning of a wide range of research applications, including cancer treatments, cell multiplication, and vaccine manufacture.
| Attribute | Details |
|---|---|
| North America Market Share | 37.20% |
North America dominated the global industry in 2023, accounting for around 37.20% of total revenue. The region's huge proportion can be linked to the government's increased investment initiatives, the increasing frequency of chronic diseases such as cancer, and the presence of high-quality infrastructure for clinical and laboratory research in the region.
The rising frequency of chronic and infectious diseases, combined with a greater emphasis on cell-based treatments, is broadening the market's potential prospects.
Due to increased demand for innovative treatments, the Asia Pacific region to develop at a swift rate throughout the forecast period. Rising government investments and rapid infrastructure development are significant drivers of booming market expansion. Some regional businesses are receiving financing to investigate treatments for chronic diseases such as cancer.
To increase their market position, leading firms are using a variety of techniques, such as the introduction of novel products, partnerships, collaborations, mergers & acquisitions, and geographic growth.
| Date | December 8, 2021 |
|---|---|
| Company | Thermo Fisher Scientific Inc. |
| Details | Thermo Fisher Scientific Inc. purchased PPD, Inc., a well-known supplier of clinical research services. The deal, which was estimated to be worth USD 17.4 billion, was made to strengthen Thermo Fisher Scientific's position in the life sciences industry. |
| Date | April 9, 2020 |
|---|---|
| Company | Bio-Rad Laboratories, Inc. |
| Details | Bio-Rad Laboratories, Inc. purchased Celsee, Inc., a top producer of single-cell analysis tools. The goal of the acquisition was to increase the range of single-cell analytic products offered by Bio-Rad Laboratories. |
| Date | June 1, 2020 |
|---|---|
| Company | Straub Medical AG |
| Details | Straub Medical AG, a significant supplier of medical tools for the detection and treatment of venous diseases, was acquired by Becton, Dickinson and Company. The acquisition aimed to increase the range of products offered by the Company in the vascular access sector. |
The market is valued at USD 352.91 million in 2023.
The overall market is projected to surge at a 13.55% annual growth rate through 2033.
The market is estimated to be worth USD 1,257.59 million by 2033.
This segment held 47.9% of the global market share in 2022.
The tissue dissociation segment accounted for 56.55% of the total market share in 2022.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 5.1. Enzymatic Dissociation 5.2. Non-enzymatic Dissociation 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 6.1. Tissue Dissociation 6.2. Cell Detachment 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-use 7.1. Pharmaceutical and Biotechnology Companies 7.2. Research & Academic Institutes 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. South Asia 8.5. East Asia 8.6. Oceania 8.7. MEA 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Merck KGaA 18.2. Thermo Fisher Scientific 18.3. Danaher Corp. 18.4. STEMCELL Technologies 18.5. Sartorius AG 18.6. Miltenyi Biotech 18.7. PAN-Biotech 18.8. HiMedia Laboratories 18.9. F. Hoffmann-La Roche Ltd. 18.10. S2 Genomics, Inc. 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Cell Dissociation Market
